25 September, 2020
The regulatory approval and commercialisation of Luxturna in 2017 has opened the floodgates for gene therapy, with numerous clinical trials underway or rapidly approaching. Dr Tom Edwards and Dr Lauren Ayton will update Retina Australia members on the national approach to identifying and characterising people who might be eligible for these trials (through the Inherited Retinal Disease Natural History Study), as well as describing the most promising developments in the field.
This webinar will take place on Saturday 17th October at 2:00pm EST. You can find a copy of the flyer in Word version here or in PDF version here
https://retinaaustralia.com.au/webinar-event-gene-therapy-clinical-trials-and-new-developments-in-ird-research/
Other News
May 2026 CEO Message from Jonathan Brookes
May marked my first 90 days as CEO of Retina Australia, an important milestone and an opportunity to reflect. The...
April 2026 CEO Message from Jonathan Brookes
April has been another important month of building momentum — strengthening our connection with the community, growing our organisational...
March 2026 CEO Message from Jonathan Brookes
As I complete my second month as CEO of Retina Australia, I’ve been focused on two key priorities: building...